Editorial: New lights Through Old Windows: Metformin and Derivatives as Anti-Cancer Treatments

Abstract

This editorial explores the renewed interest in metformin, a classical antidiabetic drug, as a potential anticancer agent. The articles in this collection investigate metformin’s molecular mechanisms—particularly its effects on cellular metabolism, AMPK signaling, and tumor microenvironments. The editorial emphasizes metformin’s promise in enhancing therapy sensitivity and modulating immune responses in cancer, and outlines directions for future preclinical and clinical studies of metformin derivatives in oncology.